Abstract:As seen in this CME online activity (available at http://courses.elseviercme.com/694), idiopathic pulmonary fibrosis (IPF) is a specific form of chronic, progressive, fibrotic lung disease of unknown cause that is associated with substantial health-care utilization and high rates of mortality. The clinical symptoms of IPF are nonspecific and overlap with many pulmonary and cardiac diseases making differential diagnosis challenging. The American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American Thoracic Association (ATS/ERS/JRS/ALAT) guidelines strongly recommend a multidisciplinary approach to the diagnosis of interstitial lung diseases; however, there are several limitations to the feasibility of this approach in clinical practice. Although early diagnosis is relevant to any chronic, progressive, and irreversible disorder, it is crucially important that effective treatments for IPF are prescribed without delay. A window of opportunity may exist during which time treatment can have optimal outcomes. Evidence on the clinical management of IPF is rapidly evolving, and key updates were made to the most recent ATS/ERS/JRS/ALAT guidelines. The widely used combination of prednisone, azathioprine, and N-acetylcysteine has now been associated with increased risk of hospitalization and death compared with placebo in patients with IPF. These treatments and others for IPF have been mostly supportive, but recently pirfenidone and nintedanib have demonstrated efficacy in reducing functional decline and disease progression in IPF. A pooled analysis of three phase 3 studies of pirfenidone found a significant 48% reduction in all-cause mortality, and a pooled analysis of a phase 2 and two phase 3 studies of nintedanib found a significant 43% reduction in on-treatment mortality. As patient exposure to these two new drugs increases, data continue to emerge on how and when to use these medications and on how to manage their side effects. Finally, several medications targeting the fibrotic pathobiology of IPF are currently in development. Given the limited treatment options for IPF, enrollment in a clinical trial may be the best chance to delay or prevent progression of IPF. This CME-certified expert video roundtable from CHEST reviews the ATS/ERS/JRS/ALAT guidelines with a specific focus on accurate and timely diagnosis of IPF and the latest data on the treatment of IPF.

Management of progressive pulmonary fibrosis associated with connective tissue disease

Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs)

Factors for progressive pulmonary fibrosis in connective tissue disease-related interstitial lung disease

Progression of fibrosing interstitial lung disease

Diagnosis and Management of Fibrotic Interstitial Lung Diseases

Advances in the identification and management of progressive pulmonary fibrosis: perspective from Chinese experts

Advances in Targeted Therapy for Progressive Fibrosing Interstitial Lung Disease

Progressive pulmonary fibrosis: an expert group consensus statement

Fibrosing interstitial lung diseases: knowns and unknowns

Novel Therapeutic Approaches in Connective Tissue Disease-Associated Interstitial Lung Disease

Progressive pulmonary fibrosis and its impact on survival in systemic sclerosis-related interstitial lung disease

Predicting progressive phenotype in patients with fibrotic interstitial lung disease

The Role of Lung Microbiome in Fibrotic Interstitial Lung Disease—A Systematic Review

A specific phenotype of interstitial lung disease—progressive pulmonary fibrosis

Genomic Profiling for Predictive Treatment Strategies in Fibrotic Interstitial Lung Disease

Management of patients with fibrosing interstitial lung diseases

Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management

Interstitial Lung Disease in Systemic Lupus Erythematosus and Systemic Sclerosis: How Can We Manage the Challenge?

The dawn of precision medicine in fibrotic interstitial lung disease

Multidisciplinary Evaluation in Patients with Lung Disease Associated with Connective Tissue Disease

Focus on Idiopathic Pulmonary Fibrosis: Advancing Approaches to Diagnosis, Prognosis, and Treatment